Pricing Log in Create free account
Friday 6 November 2026 Export AXSM’s income statement to Excel — free account

Axsome Therapeutics, Inc.

AXSM Healthcare Biotechnology

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.

Revenue
+51.9%
EPS
+73.9%
Free cash flow
−1,078.3%
Total debt
+4.04%

Quarter to September 2026, against a year earlier

132.13 2.33 +1.80%
Market cap
$6.8B
P/E
0.0×
Fwd P/E
−49.2×
Dividend yield
—
F-score
5/9
Altman Z
6.91
Beneish M
−2.53
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Axsome Therapeutics, Inc. 10-K filed Feb 23, 2026

Fiscal year 2025 · Period ended Dec 31, 2025 · Filed · accepted 5:02 PM ET · Document on sec.gov · Filing index

What changed

Item 1, Business Item 1A, Risk Factors Item 7, Management’s Discussion and Analysis

Item 1, Business, against the 10-K filed Feb 18, 2025: 31 added · 57 removed · 61 modified; 4 with only figures updated

  1. Modified · OVERVIEW

    We are a fully integrated biopharmaceutical company dedicated to the development and delivery of transformative focused on developing innovative medicines for people impacted by central nervous system, or (CNS,) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and developdeveloping differentiated products with a focus on novel mechanisms of action, that enable meaningful advancements in patient outcomes. Together, we are on a mission have the potential to solve some of the brain’s biggest problems so patients and their loved ones can flourishtransform patient outcomes.